Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.

F. Albach Marie C. Rehm M. Hütter-Krönke Thanh Hang Le Julia M. Giezen Murat Torgutalp Arne Sattler I. Minopoulou R. Biesen Edgar Wiebe V. Casteleyn Thorben Witte Christian Furth J. Zernicke Melanie Nuesch Germano J. Verhagen Artur Wilhelm M. Dzamukova Klaus Engel S. Schallenberg A. Kannt N. Ziegler M. Fehringer Udo Schneider N. Unterwalder Mark Beling Alexander Pfeil Elpida Phithak Martin Krusche Olaf Penack Tobias Alexander Werner Stenzel M. Wuhrer K. Movassaghi Thomas Doerner E. Latz T. Vogl A. Busse G. Schett H. Scherer R. Toes A. Kleyer U. Keller L. Bullinger David Simon G. Krönke
Aug 2026 · Nature Medicine · 0 citations · 55 references
Medicine

TL;DR

CD19 CAR T cells showed acceptable short-term tolerability in patients with treatment-refractory RA, justifying further evaluation, and the primary endpoint was met, allowing advancement to phase 2.

DOI PubMed Semantic Scholar
View source

Similar papers

Open access Sep 2026

A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial

Early-phase studies of deep B cell depletion with anti-CD19 chimeric antigen receptor (CAR) T have produced prolonged, drug-free remission in refractory autoimmune disease. However, CAR T cell therapy requires lymphodepleting chemotherapy, autologous cell manufacturing and specialized infrastructure, limiting reach to...

Jason Xu, Chun-Li Mei, Xin Guan et al. · 0 citations
Open access Jul 2026

Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data.

The results demonstrate the importance of continuous patient monitoring and management during CAR-T therapy and demonstrate an evolving treatment landscape, including more aggressive management of CRS and interest in preventive therapies for CRS and ICANS.

M. Frigault, R. Maziarz, T. Amoloja et al. · 0 citations
Review Open access Aug 2026

Recognition and management of early complications in CAR-T cell therapy and virus-specific T-lymphocyte therapy: a practical clinical reference

This review summarizes current recommendations for identifying, assessing, and treating early problems that can occur after CAR-T cell therapy and VST administration, and summarizes a differential diagnosis of overlapping syndromes, pediatric-specific adaptations, ICU escalation criteria, and a clinical monitoring sche...

M. Ussowicz, E. Jakubczyk, Tomasz Wróbel et al. · 0 citations
Open access Sep 2026

Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis

Low dose anti CD19 CAR T cell therapy was safe, penetrated the CSF effectively, reduced intrathecal humoral activity, modulated peripheral immune tone, and appeared to stabilize EDSS scores, which support the continued investigation of CAR T cell therapy in MS.

S. Gupta, M. Seshadri, R. Dandekar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.